No Clear Superiority Between Dapagliflozin and Empagliflozin for CAD
Neither dapagliflozin nor empagliflozin demonstrates clear superiority over the other for coronary artery disease (CAD) outcomes in patients with type 2 diabetes. Both SGLT2 inhibitors are recommended with equal strength for reducing cardiovascular events in patients with established atherosclerotic cardiovascular disease (ASCVD), including CAD 1, 2.
Evidence from Guidelines
The most recent guidelines treat these agents as interchangeable for CAD:
CCS/CHFS 2021 Guidelines explicitly recommend "an SGLT2 inhibitor, such as empagliflozin, canagliflozin, or dapagliflozin be used for treatment of patients with type 2 diabetes and atherosclerotic CV disease to reduce the risk of HF hospitalization and death" with equal strength 1.
ESC 2020 Guidelines state that "empagliflozin, canagliflozin, or dapagliflozin are recommended in patients with T2DM and CVD, or at very high/high CV risk, to reduce CV events" without distinguishing between them 2.
ADA 2024 Standards similarly recommend SGLT2 inhibitors as a class for patients with established ASCVD, noting that "the benefits seen in this patient population likely represent a class effect" 3.
Real-World Comparative Evidence
The highest quality recent comparative studies show no meaningful difference:
A 2023 Korean nationwide cohort study (366,031 patients) found no significant difference in composite cardiovascular outcomes between dapagliflozin and empagliflozin users (HR 0.93,95% CI 0.855-1.006) 4. While dapagliflozin showed lower risks of heart failure-related events and cardiovascular death in this Asian population, these findings require validation in other populations.
A 2025 meta-analysis of 428,940 participants demonstrated no significant differences between empagliflozin and dapagliflozin for all-cause death, cardiovascular death, major adverse cardiovascular events, myocardial infarction, or stroke 5.
A 2026 Korean primary prevention cohort (135,559 patients without established CVD) found comparable effectiveness between the two agents (HR 0.98,95% CI 0.89-1.09) 6.
Practical Decision-Making for Your Patient
For your patient with type 2 diabetes on gliclazide 120 mg initiating basal insulin:
Choose either dapagliflozin 10 mg or empagliflozin 10 mg daily - the choice can be based on:
- Cost and formulary availability - this is the primary differentiator given equivalent efficacy
- Renal function considerations - both can be initiated at eGFR ≥20 mL/min/1.73 m² 7
- Patient-specific factors - prior experience with either agent, insurance coverage
Key Management Points
- Reduce gliclazide dose when initiating the SGLT2 inhibitor to minimize hypoglycemia risk, especially with concurrent insulin initiation 7
- Monitor for volume depletion - consider proactive diuretic dose reduction if the patient is on diuretics 7
- Implement sick day protocols - hold SGLT2 inhibitor during acute illness to reduce ketoacidosis risk, particularly important with insulin use 7
- Counsel on genital hygiene to reduce mycotic infection risk 7
Common Pitfall to Avoid
Do not delay SGLT2 inhibitor initiation waiting to "optimize" other therapies first. The guidelines support early initiation in patients with established ASCVD regardless of glycemic control status 1. The cardiovascular benefits appear independent of glucose-lowering effects 3.
Monitoring Strategy
- Check renal function 1-2 weeks after initiation (expect small reversible eGFR decline)
- Assess for hypoglycemia and adjust gliclazide/insulin doses accordingly
- Continue SGLT2 inhibitor even if eGFR falls below initiation threshold unless dialysis is required 7
The evidence does not support choosing one SGLT2 inhibitor over the other for CAD prevention - both provide robust cardiovascular protection with similar safety profiles 1, 3, 1, 5, 4.